The third study, conducted in India, found that C-103 was over 97% effective in eliminating the adverse gastro-intestinal effects associated with weight loss medication orlistat.
Orlistat is the best-selling weight loss drug of all time with peak sales of over US$900mln in 2007, but use is limited by so-called “socially unacceptable bowel-related side effects” - namely incontinence and “flatus with discharge”.
FDA research found that over 90% of orlistat users have experienced “underwear issues”.
C-103 is a novel formulation of the drug designed to reduce these unpleasant side effects.
Thursday’s findings are consistent with the first and second of the three pilot study findings announced in August, which both found C-103 was over 98% effective in eliminating the side effects.
"M Pharma's review and assessment of these three studies fully supports our business objective to advance toward the commercialization of C-103, with the goal of helping millions of people to reach and maintain a healthy weight,” added chief executive Brian Keane.